Invention Grant
- Patent Title: In vivo engineered cereblon protein
-
Application No.: US16536227Application Date: 2019-08-08
-
Publication No.: US10781239B2Publication Date: 2020-09-22
- Inventor: David Weinstein , Benjamin F. Cravatt , Matthew Patricelli , Dean Stamos , Gabe Simon , Benjamin Horning , Ekaterina Vinogradova , Brian Nordin , Kristen Baltgalvis , Todd Kinsella
- Applicant: Vividion Therapeutics, Inc. , The Scripps Research Institute
- Applicant Address: US CA San Diego US CA La Jolla
- Assignee: VIVIDION THERAPEUTICS, INC.,THE SCRIPPS RESEARCH INSTITUTE
- Current Assignee: VIVIDION THERAPEUTICS, INC.,THE SCRIPPS RESEARCH INSTITUTE
- Current Assignee Address: US CA San Diego US CA La Jolla
- Agency: Wilson Sonsini Goodrich & Rosati
- Agent Kristin Eaton
- Main IPC: C07K14/47
- IPC: C07K14/47 ; C07D211/94

Abstract:
Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
Public/Granted literature
- US20200216507A1 IN VIVO ENGINEERED CEREBLON PROTEIN Public/Granted day:2020-07-09
Information query